Eliminate Coronary Artery Disease (ECAD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Sudbury, Ontario, Canada, P3A 2A3
- Dr. Killian De Blacam Family Medical Practice
-
Sudbury, Ontario, Canada, P3E 3C6
- Dr. Gregory Garrioch Family Medical Practice
-
Sudbury, Ontario, Canada, P3E6C3
- Dr. Reena Dhatt
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men 35-50 years of age
- Women 45 - 59 years of age (must be sterile or >2 years postmenopausal)
- LDL cholesterol greater than 1.8 mmol/L (70 mg/dL) based on testing performed within 1 year
- One risk factor for Coronary Heart Disease other than lipid abnormality:
- Obesity and hypertension [BP >140 mmHg systolic and waist circumference > 100 cm in men and >90 cm in women]
- family history of premature myocardial infarction [<60 years]
- South Asian ethnic history
- currently smoking
Exclusion Criteria:
- Currently taking cholesterol lowering medication
- Qualify for cholesterol lowering medication based on current guidelines
- Significant renal dysfunction (creatinine clearance <30 ml/min)
- Significant hepatic dysfunction (AST/ALT >2.0 times upper limit of normal)
- Active malignancy
- Diabetes
- Progressive or terminal illness, or other condition in which subject is unlikely to survive the study period
- Known allergy, hypersensitivity (anaphylaxis) ar adverse reaction to any statin
- Participation in a clinical trial (except observational studies) within previous 30 days
- Received any investigation product within 30 days prior to participation in this clinical trial
- Previously enrolled in this clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Atorvastatin
Atorvastatin(Lipitor) in addition to the usual guideline based care
|
20 mg of atorvastatin daily
Other Names:
|
|
No Intervention: Guideline based care
Current guidelines for lipid-management in healthy middle aged men and women only.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause in the follow up period
Time Frame: Up to 10 years
|
Up to 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dr Michael Farkouh, MD, FRCPC, MSc, FACC, Peter Munk Cardiac Centre, University Health Network
- Principal Investigator: Michael J Domanski, MD, University of Maryland Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
Other Study ID Numbers
Other Study ID Numbers
- ECAD001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.